Supplemental Table 1: Comparison of HCRU between SPC and MPC cohorts (absolute numbers; based on matched cohorts).

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **BIS/AMLO** | | **VAL/AMLO** | | **CAR/AMLO** | | **VAL/AMLO/HCTZ** | | **RAMI/AMLO** | | **EZE/ATOR** | | **ASA/ATOR/RAMI** | |
| **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** |
| Number of all-cause GP visits ppy | 4.19 | **4.51** | 4.59 | **4.68** | 4.26 | **4.45** | 4.63 | **5.12** | 4.31 | **4.48** | 4.49 | **4.82** | 4.30 | **4.68** |
| Number of all-cause specialist visits ppy | 0.41 | **0.64** | 0.57 | **0.65** | 0.51 | **0.53** | 0.67 | **0.71** | 0.36 | **0.48** | **1.58** | 1.40 | 1.10 | **1.51** |
| Number of all-cause hospitalization days ppy | 2.58 | **5.29** | 0.78 | **1.09** | 0.24 | **0.49** | 0.73 | **1.69** | 0.34 | **0.62** | 0.61 | **1.08** | 0.40 | **2.33** |
| Number of CV-prescriptions1 ppy | 3.04 | **5.25** | 2.75 | **3.11** | 3.08 | **3.34** | 2.83 | **7.90** | 1.98 | **2.64** | 3.40 | **5.70** | 3.08 | **4.74** |
| Number of all-cause prescriptions ppy | 7.59 | **10.13** | 7.26 | **7.81** | 7.32 | **7.48** | 7.57 | **15.97** | 5.00 | **6.10** | 8.07 | **12.26** | 7.20 | **10.97** |

BIS/AMLO= bisoprolol/amlodipine; VAL/AMLO= valsartan/amlodipine; CAR/AMLO= candesartan/amlodipine; VAL/AMLO/HCTZ= valsartan/amlodipine/hydrochlorothiazide; RAMI/AMLO = ramipril/amlodipine; EZE/ATOR = ezetimibe/atorvastatin; ASA/ATOR/RAMI = acetylsalicylic acid /atorvastatin/ramipril; ppy= per patient-year. Bold= higher value

1 CV-prescriptions: any prescribed agent with ATC-Code C-

*Legend: Supplemental Table 1 outlines the absolute results of the HCRU analysis. All numbers were reported per observed patient-year (ppy).*